The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| DOMH | +249.78% | -76.27% | -24.98% | -100% |
| S&P | +13.02% | +80.03% | +12.46% | +7,370% |
Dominari Holdings, Inc. is a biotechnology development company, which engages in the provision of diversified portfolio of small-molecule anticancer and antiviral therapeutics in development. Its oncology therapeutics includes treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It also creates a broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. The company was founded by Gilbert V. Levin and M. Karen Levin in 1967 and is headquartered in New York, NY.
No news articles found for Dominari.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $50.82M | 1157.0% |
| Gross Profit | $50.70M | 1194.0% |
| Gross Margin | 99.76% | 2.8% |
| Market Cap | $100.44M | 925.3% |
| Market Cap / Employee | $3.46M | 0.0% |
| Employees | 29 | 0.0% |
| Net Income | $126.08M | 3094.1% |
| EBITDA | -$1,475.00K | 52.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $5.37M | 57.9% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.46M | -10.3% |
| Short Term Debt | $530.00K | 31.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 82.74% | 125.3% |
| Return On Invested Capital | -30.78% | 1.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4,913.00K | -4.2% |
| Operating Free Cash Flow | -$4,913.00K | -4.2% |
| Metric | Q3 2025 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 1.28 | - | |||
| Price to Book | 0.14 | 0.58 | 1.65 | 1.12 | 388.70% |
| Price to Sales | 0.38 | 1.73 | 1.53 | 1.23 | 31.85% |
| Price to Tangible Book Value | 0.14 | 0.58 | 1.65 | 1.12 | 388.70% |
| Enterprise Value to EBITDA | -0.02 | -0.85 | -2.93 | 34.55 | -1481.12% |
| Return on Equity | -31.7% | -92.7% | -29.3% | 88.9% | -289.24% |
| Total Debt | $3.04M | $2.92M | $2.86M | $2.99M | -4.95% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
